Overview
When a protein expresses itself, Proteome Sciences is ready to measure it and put it to work. Through its PS Biomarker Services contract research organization, the company conducts protein biomarker discovery, tagging, and assay development to customers in the pharmaceutical and diagnostics industries. The company has also identified and amassed a library of biomarkers (proteins involved in disease) which it licenses out to pharmaceutical firms.
...
Read More Its focused on identifying biomarkers found in cancer and neurological and neurodegenerative conditions. Proteome Sciences was founded in 1994 and maintains research facilities in the UK and Germany.
Read Less
Read More Its focused on identifying biomarkers found in cancer and neurological and neurodegenerative conditions. Proteome Sciences was founded in 1994 and maintains research facilities in the UK and Germany.
Read Less
Christopher Donovan James Pearce
See more contacts
Management of Companies and Enterprises
,
Holding companies, nec
?
?
Estimated
$6.20 million
Actual
-2.8%
$9
DEC
?
?
London SETS:PRM
Contacts
Get in Touch with 7 Principals* and 13 Contacts
-
Christopher Donovan James PearceDirector and Chief Executive Officer
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue 2024
$6.20 million
USD
Actual
1 USD = 0.7888 GBP
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | -$1 | -$1 | $3 |
| Net Investing Cash | -$0 | -$1 | -$0 |
| Net Financing Cash | $0 | -$1 | -$0 |
| Net Change in Cash | -$1 | -$2 | $2 |
| Cash at Beginning of Period | $3 | $5 | $3 |
| Cash at End of Period | $1 | $3 | $5 |
| Capital Expenditure | -$0 | -$0 | -$0 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $1 | $3 | $5 |
| Accounts Receivable | $0 | $1 | $1 |
| Inventories | $1 | $1 | $1 |
| Other Current Assets | $1 | $1 | $1 |
| Asset Summary | |||
| Total Current Assets | $3 | $5 | $9 |
| Tangible Fixed Assets | $3 | $4 | $2 |
| Intangible Assets | $ | $ | $ |
| Total Assets | $9 | $11 | $12 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $1 | $1 | $1 |
| Short-Term Debt | $16 | $14 | $14 |
| Other Current Liabilities | $1 | $1 | $1 |
| Liability Summary | |||
| Total Current Liabilities | $18 | $16 | $16 |
| Long-Term Debt | $0 | $ | $ |
| Other Long-Term Liabilities | $ | $ | $ |
| Total Liabilities | $20 | $18 | $17 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $4 | $4 | $4 |
| Retained Earnings | -$97 | -$92 | -$89 |
| Equity Summary | |||
| Total Equity | -$8 | -$4 | -$1 |
| Shares Outstanding | 295,182,056 | 295,182,056 | 295,182,056 |